Artiva Biotherapeutics, Inc. · NASDAQ:ARTV
Artiva Biotherapeutics — Post-EULAR Virtual Webcast (June 2026)
37 slides from Artiva Biotherapeutics's conference presentation, Jun 8, 2026
Slide 1: Artiva Biotherapeutics Post-EULAR Virtual Webcast
Artiva Biotherapeutics Post-EULAR Virtual Webcast June 8, 2026
Slide 2: Disclaimers and Forward-looking Statements
Disclaimers and Forward-looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking
Slide 3: Agenda
Agenda Dr. Fred Aslan CEO Artiva Bio 10’ Introduction Dr. Diego Miralles 15’ AlloNK® EULAR update President and Head of R&D 15’ KOL impressions Artiva Bio 15’ Q&A Dr. Paul Emery Arthritis UK Professor of Rheumatology University of Leeds Artiva Biotherapeutics 3
Slide 4: Introduction
Introduction artiva>
Slide 5: Opportunity Summary
Opportunity Summary 1 Deep B-cell depletion – potent mechanism vis-à-vis other novel approaches 2 Strategic interest across modalities (auto-CAR-T, TCE, in vivo, allo) 3 Refractory RA – approx. $5B* being spent on patients unlikely to respond after failed 2+ b/tsDMARDs 4 AlloNK activity and tolerabi
Slide 6: B-Cell Depletion and "Reset" Hypothesis
B-Cell Depletion and “Reset” Hypothesis Role of B cells in autoimmune disease: Autoantibody Rituximab 1 production / tissue damage “Dimming” 2 Antigen “Reset” with naive / transitional presentation / T cell B cell phenotype amplification Cytokine secretion / 3 inflammation Durable benefit Transient
Slide 7: AlloNK: CD16 is a strong cell activating receptor, driving ADCC against B cells
AlloNK: CD16 is a strong cell activating receptor, driving ADCC against B cells 1 AlloNK (NK cell) Supportive CY/FLU 3 conditioning B-cell Rejection Antigen CD16 Pathogenic B-cell X • CD8/CD4 rejection • NK rejection (missing self) • HLA ab (ADCP- macrophage, ADCC- NK, neutrophils) B-cell targeting
Slide 8: Consistent Activity Observed Across Indications
Consistent Activity Observed Across Indications N=14 aNHL, N=24 r/rHL, Over 70 Autoimmune Patients Initiated Treatment as of April 30, 2026 Includes all patients with 3+ months of follow-up in IIT and Basket Study N = 14 aNHL N = 11 SjD N = 5 SSc N = 21 RA CRR % mDoR (mo) CDAI (change) ClinESSDAI (c
Slide 9: The Unmet Need in RA: Poor Responses in Patients who Failed 2+ b/tsDMARDs
The Unmet Need in RA: Poor Responses in Patients who Failed 2+ b/tsDMARDs b/tsDMARD line 1st 2nd 3rd and later 100 75 The RA “Ceiling Effect” AlloNK’s goal: ACR50 in ≥50% of refractory RA % of RA patients patients 50 45% achieving 39% 36% ACR50 27% Response 25 20% 19% 11% 13% 0 Upa (JAK) [1] Adalimu
Slide 10: ~$5B Spent on US RA Patients Who Failed 2+ b/tsDMARDs
~$5B Spent on US RA Patients Who Failed 2+ b/tsDMARDs 1.5M Total Diagnosed U.S. Prevalence [1] Moderate/Severe: 55% [1] Mild: 45% [1] 820k treated w/ csDMARD (e.g. MTX) ~575k treated with b/tsDMARDs [2] US RA market: ~$20B/yr[3-6] 150-200k ~$5B/yr (25%*) spent on Failed 2+ patients with 80-90% chanc
Slide 11: Registrational Strategy
Registrational Strategy • Single registrational RCT • N = ~150 RA pts with inadequate response to 2+ b/tsDMARDs Design • Randomized 2:1 to AlloNK + RTX vs. RTX-only • RTX-only non-responders may cross over into AlloNK + RTX arm at 6 months • Primary efficacy endpoint: ACR50 at 6 months Endpoint • Ex
Slide 12: AlloNK EULAR Update
AlloNK® EULAR Update artiva> 12
Slide 13: Artiva Data Updates at EULAR 2026
Artiva Data Updates at EULAR 2026 Poster Session: Robust and Durable Clinical Responses Observed Following Treatment with AB-101, an Allogeneic NK Cell Therapy, Combined with Rituximab in Patients with Severe Rheumatoid Arthritis and A Inadequate Response to Multiple Prior Targeted Therapies Late-Br
Slide 14: IIT in RA: First Allogenic Cell Therapy in RA, Showing Deep CDAI and DAS28 Responses
IIT in RA: First Allogenic Cell Therapy in RA, Showing Deep CDAI and DAS28 A Responses in Highly Refractory Patients Parameter Values (n=6) Demographics CDAI DAS28-ESR (mean 50.8 baseline) (mean 7.1 baseline) Age (y), mean (SD) 49.2 (12.0) Female, % 100% 0 0.0 -0.5 Disease Duration (y) 19.0 (9.4) -1
Slide 15: Phase 2a Basket: Highly Refractory RA Patients with High Baseline Disease Activity
Phase 2a Basket: Recruited Highly Refractory RA Patients with High Baseline Disease B Activity as of April 3, 2026 Data Cutoff Parameter Values (n=15) Demographics Age (y), mean (SD) 53.9 (11.36) Female, % 15 (100%) Disease Duration (y) 13.3 (10.98) Region US only Disease Activity CDAI, mean (SD) 50
Slide 16: Consistent Deep CDAI and DAS28 Responses, with 71% ACR50 at 6 Months
B Consistent Deep CDAI and DAS28 Responses, with 71% ACR50 at 6 Months CDAI DAS28-ESR DAS28-CRP ACR Response (Baseline mean= 50.7) (Baseline mean = 7.4) (Baseline mean = 6.7) ACR50 ACR20 Mean Change from Baseline (±SEM) 100% 0 0.0 0.0 29% -5 -0.5 -0.5 -10 -12 -15 -1.0 -1.0 -1.2 -1.2 -20 -1.5 -1.5 -2
Slide 17: Combination of RA Datasets: Durability of Response Observed Across Studies
Combination of RA Datasets: Durability of Response Observed A B Across Studies Months IIT 0 3 6 9 12 15 18 21 Ph2a Basket RA-1 ✓ RA-2 AlloNK treatment cycle RA-3 ✓ RA-4 On-study; no steroids beyond “soft ✓ rescue”; no new b/tsDMARDs RA-5 ✓ RA-6 ✓ ACR50/mACR50 at 6 months RA-7 ✓ RA-8 ACR50/mACR50 ach
Slide 18: SjD Patient Case Study: First Patient Treated
SjD Patient Case Study: First Patient Treated Showed Dramatic Initial Response and C Improvement Across All Domains of ClinESSDAI and ESSPRI ClinESSDAI ClinESSDAI Domains 23.0 Improvement in all clinical • Disease Duration: 6 measures: Domain BL 12.5y mo From baseline to 6 months • Autoab: Anti-SSA/
Slide 19: Phase 2a, SjD: Initial Responses Across Clinical Measures and Function
B Phase 2a, SjD: Compelling Initial Responses Across Clinical Measures and Function ClinESSDAI ESSPRI SSF (mL/min) Baseline Characteristics (n=11) (Mean +/- SEM) • Age (y), mean (SD): 53.6 0 0.0 1.5 Mean change from baseline (± SEM) (14.66) -1 • Sex: 100% female -2 -0.5 • Disease duration (y), mean
Slide 20: Phase 2a, SSc: Initial Response Across Clinical Measures
B Phase 2a, SSc: Initial Response Across Clinical Measures mRSS rCRISS at 6 months Baseline Characteristics (n=5) (n=4) Mean change from baseline (± SEM) 0 • Age (y), mean (SD): 54.2 (12.85) -1 • Sex: 40% Female -2 -3 • Disease duration (y), mean (SD): 4.1 -4 (2.96) -5 MCII 4/4 • Modified Rodnan sco
Slide 21: Tolerability Profile of AlloNK + RTX Compared to Autologous CAR-T and T-Cell Engagers
Tolerability Profile of AlloNK + RTX Observed Compared Favorably to E Autologous CAR-T and BCMA Targeted T-Cell Engagers Deep B-cell Depletion Datasets AlloNK + Auto CAR-T T-Cell Engager Schett / CASTLE1 teclistamab2 Comparable to Serious Infection ritux Rates for Approved RA therapies3: No. of Pati
Slide 22: Experience in First 55 Autoimmune Patients Treated with AlloNK + RTX
Experience in First 55 Autoimmune Patients Treated with AlloNK + RTX E Hospitalization Rates Consistent with mAb Alone Showing Ability to Manage Patients as Outpatient 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 Outpatient Treatment Day Hospitalization for AE IIT 1 1 N
Slide 23: AlloNK + RTX Showed Consistent Complete B-Cell Depletion in Autoimmune Diseases
AlloNK + RTX Showed Consistent Complete B-Cell D Depletion in Autoimmune Diseases Uniform and consistent B-cell depletion B-cell Reconstitution No CD19+ B cells in single tissue observed by Day 13 in all 51 patients with Consistent with biopsy case study in RA patient autoimmune diseases “Reset” Day
Slide 24: KOL Perspective
KOL Perspective artiva> 24
Slide 25: The Unmet Need in RA: Many Patients Not Well-Controlled With Std of Care
The Unmet Need in RA: Many Patients Not Well-Controlled With Std of Care Total Diagnosed Moderate/Severe: 55% treated w/ csDMARD (e.g. MTX) • Many RA patients fail ≥2 distinct classes treated b/tsDMARDs with b/tsDMARDs [2] • Despite 5 approved drug classes, there is substantial unmet clinical need a
Slide 26: The Unmet Need in RA: Poor Responses in Patients who Failed 2+ b/tsDMARDs
The Unmet Need in RA: Poor Responses in Patients who Failed 2+ b/tsDMARDs Real-World ACR50 Response in Patients Who Failed 2+ Prior b/tsDMARD Classes 100 75 • Existing SoC delivers low response rates, leaving % of RA physicians to cycle through therapies without patients achieving disease control ac
Slide 27: High-Sensitivity B-Cell Assay Reveals Incomplete Depletion with Rituximab Alone
High-Sensitivity B-Cell Assay Reveals Incomplete Depletion with Rituximab Alone and Higher Response Rate in Patients with Complete Depletion Incomplete Depletion with Higher Response Rate With Complete B-Cell Depletion RTX Alone Median level of B-cells (cells/µl) at Percent of patients with a modera
Slide 28: High-Sensitivity B-Cell Assay: Complete Depletion with AlloNK + RTX
High-Sensitivity B-Cell Assay Reveals Incomplete Depletion with Rituximab Alone and Higher Response Rate in Patients with Complete Depletion Incomplete Depletion with Complete Depletion with AlloNK + RTX RTX Alone Median level of B-cells (cells/µl) at B-cells (cells/µl) at nadir using 2 weeks using
Slide 29: B-Cell Repopulation Following Complete Depletion is Consistent with "Reset"
B-Cell Repopulation Following Complete Depletion is Consistent with “Reset” B-Cell Repopulation with Higher Memory Cell Ratio in Patients with Complete Depletion Reconstitution of B cells 6 months after therapy1 • 60 RA patients treated at Leeds; RF or CCP+, failed anti-TNF naïve B cells • B cells m
Slide 30: B-Cell Reconstitution Following AlloNK + RTX
B-Cell Repopulation Following Complete Depletion is Consistent with “Reset” B-Cell Repopulation with Higher Memory Cell Reconstitution Following Ratio in Patients with Complete Depletion AlloNK + RTX Reconstitution of B cells 6 months after therapy1 AlloNK + RTX • 60 RA patients treated at Leeds; RF
Slide 31: Artiva Enrolled Patients with Long-Standing Disease and High Baseline Disease Activity
Artiva Enrolled Patients with Long-Standing Disease and High Baseline Disease Activity – Very Hard to Treat with Standard of Care • Long disease duration – likely long-term joint damage that is not fully reversible • Very high baseline disease activity – unlikely to respond dramatically to existing
Slide 32: AlloNK + RTX Clinical Responses Were Far Beyond Historical Data with RTX Alone
AlloNK + RTX Clinical Responses Were Far Beyond Historical Data with RTX Alone • No controlled clinical trials have specifically been conducted in patients who failed 2+ b/tsDMARD classes • In less refractory (failed only anti-TNF) RA patients, rituximab showed 2.0 point decrease in DAS28-ESR and 27
Slide 33: Emerging Data Shows Durable Response from Single Treatment Cycle
Emerging Data Shows Durable Response from Single Treatment Cycle • Patients managed without starting new b/tsDMARD – real- world measure of therapeutic durability • Many patients with ACR50 by 3 months, but more by 6 months (pivotal study end-point) • Consistency from initial PoC (IIT) to Phase 2a A
Slide 34: Closing Remarks
Closing Remarks artiva> 34
Slide 35: Program Commercial Objectives
Program Commercial Objectives “Enough! Time for cell therapy” • To be the first FDA-approved deep B-cell depleting therapy for refractory RA patients who have failed 2+ b/tsDMARDs • To be a one-time treatment (“reset”) lasting more than 18 months with several patients still benefiting 3 years later;
Slide 36: Multiple Potential Catalysts Through RCT Readout
Multiple Potential Catalysts Through RCT Readout H2’26 H1’27 H2’27 H1’28 H2’28 RA 15+ pts w/ ACR50@6m 50+ total pts w/ 18-36 mos f/u open-label update: • 40+ pts w/ ACR50@6m • 20+ pts w/ 12-18+ mos f/u RA RCT Trial initiation Enrollment complete RCT read-out Second indication Plans for second indica
Slide 37: Q&A
Q&A artiva> 37
Artiva Biotherapeutics — Post-EULAR Virtual Webcast (June 2026) on 6ix